Roche’s newly acquired subsidiary TIB Molbiol has developed three new test kits to detect mutations in the new Omicron variant of Covid-19.

The three new Research Use Only (RUO) test kits include VirSNiP SARS-CoV-2 Spike S371L S373P, VirSNip SARS Spike ins214EPE and VirSNip SARS Spike E484A.

They are intended to help researchers differentiate the unique mutations in the Omicron variant from other Covid-19 variants.

Roche noted that the VirSNiP variant kits are designed for use on LightCycler and cobas z 480 analysers.

They use quantitative polymerase chain reaction (qPCR) technology to help researchers improve variant detection and viral research.

The new RUO test kits will help evaluate the spread of new Covid-19 variants as well as observe the potential impact of vaccines, public health interventions and therapies on the spread of variants.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Roche Diagnostics CEO Thomas Schinecker said: “The Covid-19 pandemic continues to be an evolving and complex situation, and Roche is committed to responding to healthcare’s biggest challenges.

“The teams at TIB Molbiol have worked around the clock since the new variant emerged, and today we are able to offer a test that can specifically identify the novel B.1.1.529 Omicron SARS-CoV-2 variant to help better understand its spread and behaviour.

“There is still much to learn about Omicron. It’s critical to identify Omicron quickly and accurately, which will help inform ongoing research – including the further development of therapeutics and vaccines – and potentially stop or slow down the advance of this new variant.”

The company claims that the VirSNiP variant kits are among the first to detect the new Omicron variant mutations.

After analysing the new Omicron variant’s sequences, Roche has also concluded that all its PCR tests can identify Covid-19 as well as its new variant.

Last month, Roche launched cobas 5800, a new molecular diagnostics system, to expand access to testing and improve patient care.